Sign in
Enrolling by invitationNo phase

Tests a sleep treatment for insomnia in adults at risk of heart disease

Tests an updated insomnia therapy in adults with insomnia and heart disease risk factors.

Key facts

Who runs it
Indiana University
Where
Indianapolis, United StatesSee the site
Trial code
Registry title
SHADES Mechanistic Trial
Status
Enrolling by invitation
People taking part
200 people, planned
Started
25 Apr 2024
Expected to end
31 Jul 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sleep Healthy Using The Internet (SHUTi)
  • Telephonic CBT-I
  • Face-to-Face CBT-I
  • Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care
Record updated
6 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for primary care patients aged 40 or older who have insomnia disorder and several heart disease risk factors but no heart disease yet.

Age
40 years or older
Sex
All sexes
Disease stage
Current insomnia disorder, confirmed by an interview. Raised heart disease risk: at least 2 risk factors if aged 40-59, at least 1 if aged 60 or older (high blood pressure, high cholesterol, diabetes or smoking).
Biomarker or test result
Insomnia Severity Index score of 10 or more at screening.

Main reasons for not taking part

  • History of heart or blood vessel disease, such as heart attack, coronary artery disease, heart failure or stroke
  • Another sleep disorder, such as sleep apnea, or CPAP use
  • Major inflammatory conditions: HIV/AIDS, chronic kidney disease, systemic inflammatory disease or active cancer
  • Current pregnancy
  • Bipolar disorder or psychosis, severe cognitive impairment, or acute risk of suicide

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Current primary care patient in Eskenazi Health
  • Age ≥40 years
  • Current insomnia disorder: During screening, ResNet assistants will administer the Insomnia Severity Index (ISI), a validated screener in primary care. Patients who have ISI scores ≥10 (97% sensitivity, 64% specificity) and remain eligible after ResNet screening will be called by our Insomnia Clinical Specialist, who will administer the Structured Clinical Interview for DSM-5 Sleep Disorders to confirm insomnia disorder
  • Elevated CVD risk: Elevated CVD risk will be defined as ≥2 (if 40-59 years) or ≥1 (if 60+ years) of the following risk factors in the Eskenazi Health EHR in the past 5 years: hypertension, hypercholesterolemia, diabetes, or smoking

Who cannot take part

  • History of clinical CVD: a self-reported CVD diagnosis during screening or any of the following in the patient's electronic health record before enrollment: myocardial infarction, unstable angina, coronary artery disease, cerebrovascular disease, heart failure, percutaneous coronary intervention, or coronary artery bypass graft
  • Sleep disorder diagnosis other than insomnia (e.g., sleep apnea)
  • Major inflammatory conditions (HIV/AIDS, chronic kidney disease, systemic inflammatory disease, or active cancer)
  • Severe cognitive impairment (≥3 errors on a validated 6-item cognitive screen)
  • History of bipolar disorder or psychosis
  • Continuous positive airway pressure (CPAP) use or a STOP-BANG Questionnaire score ≥5, which is indicative of high probability of sleep apnea
  • A schedule requiring a usual bedtime earlier than 8:00pm or later than 2:00am or arising time earlier than 4:00am or later than 10:00am
  • Current pregnancy
  • Acute risk of suicide

Where in United States

  • Department of Psychology, School of Science, Indiana University IndianapolisIndianapolis, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

Cardiovascular disease (CVD) is common, deadly, and costly, and adults with insomnia represent a large group of people at elevated risk of developing CVD in the future. This clinical trial will determine if our updated insomnia treatment, called the SHADES intervention, improves CVD factors thought to explain how insomnia promotes CVD and if these improvements are due to positive changes in sleep factors. A total of 200 primary care patients with insomnia and CVD risk factors will be randomized to 6 months of the SHADES intervention (internet, telephonic, and/or face-to-face cognitive-behavioral therapy for insomnia) or the active control condition (sleep education/hygiene, symptom monitoring, and primary care for insomnia). Before and after treatment, participants will complete measurements of the CVD factors (systemic inflammation, autonomic dysfunction, metabolic dysregulation, proinflammatory gene expression) and the sleep factors (insomnia symptoms, sleep onset latency, wake after sleep onset, sleep efficiency). Researchers will test whether the SHADES intervention produces greater improvements in the CVD factors than the active control condition.

The 2 groups in the trial

  • SHADES InterventionTreatment being tested

    The SHADES intervention is a 6-month, modernized, collaborative care intervention in which a multidisciplinary team delivers established insomnia treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that harnesses technology to maximize access to and convenience of effective treatments and to minimize personnel, training, and space requirements. Our Intervention Team consists of an insomnia clinical specialist, a clinical behavioral sleep medicine and CBT-I delivery expert, a sleep research/medicine expert, and the patients' primary care providers. Treatments to be delivered are CBT-I in different modalities - internet, phone, and face-to-face - all of which are empirically supported.

    Treatment: Sleep Healthy Using The Internet (SHUTi), Telephonic CBT-I, and Face-to-Face CBT-I

  • Active ControlExisting treatment, for comparison

    Active Control (AC) consists of sleep education and hygiene (study staff), symptom monitoring (study staff), and usual primary care for insomnia (clinical staff).

    Treatment: Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Strengthening Hearts by Addressing DisruptEd Sleep (SHADES) Mechanistic Trial
Plain-language title
Tests a sleep treatment for insomnia in adults at risk of heart diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 August 2026